• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Spark Therapeutics Appoints CTO

    Cryoport Launches ESG Program

    U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail

    Thermo Fisher Scientific Completes Mesa Biotech Acquisition

    Ashfield Engage, Popit Form Digital Monitoring Collaboration
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Solid Dose Market Trends

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    C2 Pharma Completes Multiple Regulatory Filings

    Bormioli Opens New Glass Research Center
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing

    PwC Joins Medicines Manufacturing Innovation Centre
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Ashfield Engage, Popit Form Digital Monitoring Collaboration

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    CrownBio & JSR Life Sciences Partner with Cambridge Quantum Computing
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Emergent BioSolutions

    PCI Pharma Services

    Almac Group

    Alcami

    Adare Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Almac Group

    Emergent BioSolutions

    Syngene

    Adare Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Expanding CMO/CDMO Roles

    Supporting smaller manufacturers with end-to-end services

    Expanding CMO/CDMO Roles
    Scott Cohon, Director, Sales and Trade Relations, Woodfield Pharmaceutical, LLC05.05.20
    Pharmaceutical manufacturers are feeling the heat. With cost containment a priority, especially in an era of COVID-19 and the threat of other previously unimagined business disruptions, the race to outsource development and manufacturing of life-saving drugs to trusted service providers is accelerating.

    The race for end-to-end outsourcing with contract manufacturing organizations (CMO) and contract development and manufacturing organizations (CDMO) takes on different meanings for smaller and virtual manufacturers compared with large conventional pharmaceutical companies. With fewer financial and human resources, smaller organizations rely on their outsourcing partners for additional services that many large manufacturers retain internally. Although smaller firms have equal dependence as large drug companies on their CMO/CDMO partners, their priority is focused on a different set of service offerings.

    Origins of Outsourcing
    Manufacturing is no longer a profit center for drug companies. When the economics of the situation became apparent during the mid-1990s, financial companies and venture capital (VC) firms swooped in. Their plan involved purchasing unprofitable business units from manufacturers and running them on their behalf. During these early years, the strategy did not unfold smoothly. The VC firms underestimated the reluctance of manufacturers to forfeit control over their manufacturing operations. More recently, skepticism was replaced with willingness as companies sold manufacturing and development operations that negatively affected the bottom line.

    Outsourcing Drivers
    The current drive from pharmaceutical manufacturers for outsourcing activities along a wider stretch of the supply chain is due to several factors. 

    First, there is a growing demand for generic medicines and biologics. The U.S. Food and Drug Administration (FDA) approved 1,171 generic drugs during their fiscal year 2019, a higher quantity compared with all previous years. During the same period, the FDA approved 48 new drugs and biologics. 

    Second, the development and manufacturing of medications is a capital-intensive business. With margins shrinking for generics, manufacturers are reducing the scale of their investments within this category.
    Third, complex manufacturing methods and equipment are required for new molecular structures and for the increasing sophistication of active pharmaceutical ingredient (API) materials.

    Manufacturers conserve resources by relying on outsourcing partners to expand their role leading to product commercialization. Consolidation of development and manufacturing activities with CMO/CDMO partners reduces cost, conserves resources, enables the manufacturer to focus on drug substance development and adds flexibility with access to equipment options beyond internal capabilities. 

    One-stop Shopping
    The CMO/CDMO market is competitive and resistant to consolidation with only a few large players with global reach. The ability to differentiate services is an important factor for increased business. Promoting multiple outsourced services as a one-stop-shop for manufacturers is a popular strategy.  

    Different CMO/CDMO companies pursue this profitable goal in one of two ways. The first pathway is a vertically integrated model built around API and excipient manufacturing. The second strategy is a virtually outsourced model that centers on performing quality and regulatory services with an acquired API source.

    Vertically-outsourced Model
    Pharmaceutical manufacturers that utilize a vertically outsourced model partner with CMO/CDMO firms that create their own API, excipients and components and often maintain project management responsibilities internally.

    This one-stop-shop model applies to larger organizations partnering with large manufacturer clients with branded products and international marketing reach. 

    Many of the clients retain personnel internally specializing in regulatory, quality assurance and commercialization. Due to their size, these clients have subject-matter experts on staff to actively communicate with the CMO/CDMO and manage the project from start to finish.

    Benefits of the vertically outsourced solution include consistency of product quality in all commercial markets globally because in many cases, one company is manufacturing the API for 100% of production. 

    Virtually-outsourced Model
    Unlike vertical outsourcing, middle to small-market clients utilizing the virtually outsourced solution work with their CMO/CDMO partners to source API and all components. Virtual manufacturers and smaller manufacturers with limited financial and human resources partner with these firms. 

    Many virtual manufacturers are substantial business entities so revenue alone is not a defining quality of companies seeking the virtual outsourced model. However, many companies pursuing this route are smaller with limited resources. Regardless of the size of their bottom line, these clients also tend to rely on their outsourcing partner for project management responsibilities that are internal functions within most larger manufacturers.

    Another distinguishing characteristic for clients of CMO/CDMO companies specializing in a virtual one-stop shop model is their preference for projects with regional or national scope. Vertically outsourced firms are better equipped for commercialization on a global scale.

    Manufacturers working with virtually outsourced CMO/CDMO partners do not have the resources or expertise to develop their own API. In this scenario, the CMO/CDMO partner manages procurement of API from trusted sources and creates alliances with companies providing complementary services including Third Party Logistics (3PL) capabilities and serialization support for DSCSA compliance.

    Although large CMO/CDMO companies may perform non-core activities for clients, these tasks are generally completed with more efficiency by a smaller scale CMO/CDMO that engages in these functions on a daily basis for multiple clients.

    End-to-end Relationships
    The differences between vertical and virtual outsourcing are quantitative in terms of services provided and also qualitative regarding the relationships between parties. 

    Many manufacturers partnering with vertically outsourced CMO/CDMO companies have operations in multiple countries and employ internal teams with deep expertise in compliance, quality assurance, development, manufacturing and materials management to oversee activities of their CMO/CDMO partner. These interactions tend to be knowledge-neutral in the sense that both the client and CMO/CDMO have similar levels of expertise.

    Relationships in the virtually outsourced model tend to be weighted toward the CMO/CDMO partner in cases where a small virtual manufacturer engages a contract manufacturer to manage the entire commercialization process. In some instances, the CMO/CDMO serves as a general consultant performing non-core functions including preparation of documents for the client to submit to authorities, customs and brokerage services and third party logistics solutions.

    Examples of Virtual Outsourcing
    A typical example of virtual outsourcing involves a small virtual manufacturer that partnered with a virtually outsourced CMO/CDMO to produce a generic version of a branded medication. 

    The CMO took ownership of the challenge and identified the regulatory stages required to support their submission to the FDA for approval. Documentation was created and prepared by the CMO on behalf of the client. These documents were submitted by the client for approval. A supply agreement was completed enabling purchase of API. Throughout the process, the project manager at the CMO communicated regularly with the client to review status and progress. When the API was acquired, the CMO arranged for importation and customs clearance to the manufacturing facility. 

    With the API in hand, the CMO conducted analytical testing based on previously created scientific methods, followed by validation of all methods and materials.

    For the manufacturing process to begin, all related components and excipients were researched, acquired and tested for suitability. A coordinated effort was organized to comply with DSCSA regulations for product serialization. This client also relied on their CMO to design the product label. As a final step, the client utilized a trusted partner of the CMO for third party logistics services.

    In a second typical case, a smaller virtual manufacturer with comprehensive knowledge of pharmaceutical science that possessed less knowledge about commercialization approached a virtually-outsourced CMO/CDMO for assistance bringing their product to market. Their medication was approved in Canada and they were seeking FDA approval. The CMO/CDMO undertook the research and development required to submit proper documentation. This project included complete formulation development, analytical testing, method and material validation. Results and documentation were generated and prepared for submission by the client. In this case, the CMO/CDMO also referred the client to potential partners with sales and marketing expertise in anticipation of entry into the U.S. market. 

    Virtually outsourced CMO/CDMO companies attempt to broaden their knowledge base as much as possible because the skillset of their client base varies considerably. The virtually outsourced CMO/CDMO must be prepared for research and development projects as well as procurement of critical components—bottles, pumps, sprayers, droppers—to meet project requirements for safety, efficacy and cost. And sometimes project requirements change unexpectedly as when a client requests a custom-designed label that was not envisioned before contract signing.

    Conclusion
    The goal of innovative CMO/CDMO partners to offer ‘end-to-end’ solutions takes on different meanings depending on the desired client base. Larger-scale CMO/CDMO companies begin their end-to-end services with development and manufacture of the API and progress through each service with regular oversight by the client company. This vertically-outsourced business model focuses on large manufacturers with a global presence. These manufacturers maintain internal departments with specific knowledge of regulatory compliance, quality assurance, pharmaceutical development, sales and marketing that work alongside their CMO/CDMO partners.

    Contrast the vertically-outsourced model with the virtually-outsourced model for providing end-to-end services. CMO/CDMO companies offering virtually-outsourced solutions cater to virtual or smaller manufacturers with limited geographic reach. These CMO/CDMO partners acquire API from trusted sources and tend to oversee project management on behalf of their clients. Relationships in the virtually-outsourced model focus on guiding the client through the development and commercialization process. In many cases these clients do not have the resources to maintain subject-matter experts and therefore rely heavily on their CMO/CDMO partner for recommendations and insights to reach the finish line.

    Future Prospects
    Vertical and virtual end-to-end outsourcing models are poised for further growth. As the coronavirus pandemic compels new strategies to better prepare for future disruption, the pharmaceutical outsourcing industry will benefit from increased reliance on domestic development and production of medications to enhance security and guarantee supply. 


    Scott Cohon is the Director of Sales and Trade Relations at Woodfield Pharmaceutical, LLC.  He is responsible for expanding relationships with current clients and trading partners. In his role Scott evaluates changing needs of manufacturers and implements services that support commercialization strategies.

    Related Features

    • Solid Dosage/Creams/Ointments
      High Drug Loading Amorphous Solid Dispersions

      High Drug Loading Amorphous Solid Dispersions

      A Novel Tablet Architecture for Amorphous Solid Dispersions to Achieve High Drug Loadings
      Deanna Mudie and Aaron Stewart, Lonza 01.27.21

    • Parenterals
      Parenteral Drug Delivery Trends

      Parenteral Drug Delivery Trends

      A Q&A with Lubrizol Life Science Health’s CDMO Division President, Rob Lee.
      Kristin Brooks, Managing Editor, Contract Pharma 01.27.21

    • Selecting the Right Outsourcing Model for Emerging Biotech

      Selecting the Right Outsourcing Model for Emerging Biotech

      Flexible outsourcing models help drive quality, control costs and enable better efficiencies and faster delivery.
      Timothy King and Elisha Talley-Roithner, PPD 01.27.21


    • Drug Delivery
      Inhaled Drug Delivery Technology

      Inhaled Drug Delivery Technology

      The success of any new inhaled medicine relies in a large part on the correct combination of formulation and device technology being chosen for its delivery.
      Dr. Sandy Munro, Vice President – Pharmaceutical Development, Vectura 01.27.21

    • Biologics, Proteins, Vaccines
      The Future of Biologics: Accelerating Production, Reducing Costs

      The Future of Biologics: Accelerating Production, Reducing Costs

      Yeast-based gene expression offers pharma the yield and efficiencies it needs to make pandemic-stopping vaccines faster and more economical.
      Mark Emalfarb, Dyadic 01.27.21

    • Analytical Services | Information Technology | Laboratory Testing
      Business Intelligence For (and From) the Lab

      Business Intelligence For (and From) the Lab

      How a digital ecosystem can harness the most data-rich environment in the CDMO.
      Bob Voelkner, VP Sales and Marketing, LabVantage 01.27.21


    • Communicating Your Contracting Priorities to Your Drug Company Customers

      Communicating Your Contracting Priorities to Your Drug Company Customers

      A discussion with Perrigo’s senior legal counsel, Susan Fyan, about issues that arise in very fact-specific contract negotiations between CDMOs and sponsors.
      Stephen Sayre, Dykema 01.27.21

    • COVID-19 Impact Report

      COVID-19 Impact Report

      Leaders across the pharmaceutical contract services industry reflect on the impact of COVID-19 in 2020, and what to expect in 2021.
      Tim Wright, Editor, Contract Pharma 01.27.21

    • Biologics, Proteins, Vaccines | Regulatory Affairs
      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      A look at EUA standards and approvals, unavoidable pitfalls, Operation Warp Speed, FDA’s use of Real-World Evidence, and a slow return to “normalcy.”
      Chad Landmon, Michelle Divelbiss and Alex Alfano, Attorneys - Axinn, Veltrop & Harkrider LLP 01.27.21


    • Excipients
      Bye-Bye China?

      Bye-Bye China?

      Instead of closing its doors on China, Western pharma industry needs to take a balanced approach and perform proper due diligence based on objective criteria.
      Michele Jermini and Enrico Polastro 11.17.20

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Drug Delivery | Injectables
      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Bringing together self-medication with auto-injectors and sustainable secondary packaging.
      Matthias Heinrichs, Head of Product Management and Project Engineering, Syntegon Technology 11.17.20


    • The Single-Use Mixing Landscape: Evaluating Your Options

      The Single-Use Mixing Landscape: Evaluating Your Options

      Adoption of single-use technologies has increased markedly in recent years and will continue to grow.
      Mark A. Sitcoske, Founder & CEO, High Purity New England 11.17.20

    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      Lonza’s Director of Commercial Development, Sean Diver, was recently named President of DCAT.
      Tim Wright, Editor, Contract Pharma 11.17.20

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20

    Trending
    • Catalent Acquires Delphi Genetics
    • Inside A Vaccine Trial
    • Pfizer Selects Seven Bridges To Support RNA Sequencing Data
    • Pfizer Partners With Medicines Manufacturing Innovation Center
    • ICON Acquires Medpass
    Breaking News
    • Spark Therapeutics Appoints CTO
    • Cryoport Launches ESG Program
    • U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail
    • Thermo Fisher Scientific Completes Mesa Biotech Acquisition
    • Ashfield Engage, Popit Form Digital Monitoring Collaboration
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Preliminary Study Links Markers of Impaired Bone Health to Vegan Diet
    Refined Grains Linked to Heart Attack Risk, Early Death
    Kappa Bioscience Extends Research Partnership For COVID-19 Research
    Coatings World

    Latest Breaking News From Coatings World

    Nippon Paint Marine Wins Korea Export Award
    Universal Display Corporation, PPG Expand Global Production of UniversalPHOLED Materials
    PPG Introduces Premium Iso-free Primer Surfacer, Catalyst
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    January AI Raises $8.8 Million in New Funding
    FDA Clears Ava Fertility Tracking Wearable Device
    First Patient in Europe Treated With Diamondback 360 Coronary Orbital Atherectomy System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Spark Therapeutics Appoints CTO
    Cryoport Launches ESG Program
    U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    The Top Beauty Products of 2021, According to HelloGiggles
    Estée Lauder Taps Ana de Armas as Global Brand Ambassador
    Sephora Announces Significant Expansion
    Happi

    Latest Breaking News From Happi

    ACI Urges Senate to Approve Regan as EPA Administrator
    Estée Lauder Signs Actress Ana de Armas
    GUM Recalls Oral Spray
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Marshall & Bruce Adds Koenig & Bauer Rapida 106 41-Inch Seven-Color Press
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    FTA converts Forum & INFOFLEX to virtual events
    Xeikon launches two new digital label printing presses
    UFlex adds capacity in packaging films
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Texas Medical Technology Partners with My Protect Kit
    Mexico City Single-Use Plastics Ban Leads to Tampon Shortage
    Believe Diapers Launch in U.S.
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Fusion Robotics Receives FDA Clearance for Spinal Navigation and Robotics System
    Kaia Health Unveils Next-Gen Complete MSK Care Solutions
    First Implantation of CTL Amedica's Minimally Invasive Flex Tower
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login